Brad Walsh is Chief Executive Officer and a Director of Minomic International Ltd, an Australian immuno-oncology company that has developed an in vitro diagnostic test for the early detection of prostate cancer. Brad has been associated with proteome technology since its inception and has a PhD in protein chemistry and 30 years’ experience in the field of biotechnology. Brad has developed skills in capitalising on new opportunities, project development and management, as well as the technical and financial aspects of running biotechnology companies.